Here is a useful way to appreciate the research gap in female testosterone: the first well-controlled clinical trial demonstrating that testosterone deficiency in men causes measurable loss of muscle mass was published in 1972. The first well-controlled dose-response trial rigorously mapping testosterone’s effects on sexual function, muscle performance, and body composition specifically in women was published in 2014.
That is a 42-year gap. And the 2014 trial — the Huang, Basaria, Bhasin et al. study from Boston University — enrolled 71 women.
This is the research landscape for female testosterone. It is not barren. But it is roughly 30–40 years behind the men’s side, and in several domains, the evidence is preliminary enough that definitive clinical guidance remains genuinely difficult.
What the Evidence Actually Shows
Despite the gap, the evidence that does exist is informative. Let’s take the key domains in turn.
Sexual Function and Libido
This is the strongest area of evidence. The 2019 Global Consensus Position Statement, which synthesized data from 36 randomized controlled trials involving more than 8,000 women, concluded that testosterone is the only treatment specifically shown to improve hypoactive sexual desire disorder (HSDD) in postmenopausal women. The effect sizes are moderate but consistent — roughly 0.5 to 1.0 additional satisfying sexual events per 4-week period compared to placebo, and significant improvements on validated sexual desire and distress instruments.
Several meta-analyses have confirmed this finding. A 2019 meta-analysis by Islam et al. in The Lancet Diabetes and Endocrinology — the same year as the Global Consensus Statement — analyzed 46 randomized controlled trials and found that testosterone significantly improved sexual function across multiple domains: desire, arousal, orgasm, and pleasure. The effect was consistent across delivery methods (patch, gel, injection) and populations (surgically and naturally menopausal women).
The evidence is weaker for premenopausal women with HSDD, not because testosterone is unlikely to help, but because fewer trials have been conducted in that population, and the confounders (hormonal contraception use, relationship factors, concurrent hormonal fluctuations) make trial design more complex.
Energy and Wellbeing
The data on fatigue and psychological wellbeing are supportive but more heterogeneous. Multiple trials have shown improvements in general wellbeing and energy scores with testosterone, but the effect sizes vary and some trials have not found statistically significant improvements. Part of the problem is that “fatigue” and “wellbeing” are measured by various instruments across studies, making meta-analytic pooling noisy.
The Huang et al. (2014) dose-response study showed that testosterone dose correlated with improvements in the Psychological General Well-Being Index (PGWBI) scores — more hormone, better wellbeing scores — which supports a biological mechanism. But this was a secondary outcome, and the trial was not powered to make definitive conclusions about wellbeing alone.
Bone Density
This is an underappreciated dimension of female testosterone physiology. Testosterone contributes to bone mineral density through androgen receptor pathways and through conversion to estradiol via aromatase in bone tissue. Observational studies show that lower testosterone levels in postmenopausal women are associated with lower bone density and higher fracture risk. Some clinical trials have shown that testosterone supplementation produces modest but measurable increases in bone mineral density in postmenopausal women.
The 2019 Global Consensus Statement acknowledges bone density as a plausible benefit but does not make a formal recommendation for this indication, citing insufficient randomized controlled trial data specifically designed to assess fracture endpoints.
Muscle Mass and Physical Function
The evidence here is interesting and somewhat underutilized in clinical discussions. The Huang et al. (2014) study is the most rigorous dataset available. In surgically menopausal women randomized to graded testosterone doses over 24 weeks, those in the highest dose group (25 mg/week, bringing testosterone to approximately 210 ng/dL — above physiologic female range, notably) showed significant increases in lean body mass, chest-press power, and loaded stair-climb power compared to placebo. Lower-dose groups showed trends but did not reach statistical significance.
The implication is that testosterone does have anabolic effects in women, that those effects are dose-dependent, but that the doses required to produce measurable changes in short-duration trials may push toward or above the upper physiologic female range. This is an important nuance for clinical application: muscle benefits in women may require the high end of the physiologic range, not the low end.
What the Research Is Still Missing
The honest version of the field’s current state is that several important questions remain unanswered.
Long-term cardiovascular safety. The trials that exist are predominantly 6–12 months in duration. Whether transdermal testosterone at physiologic doses in postmenopausal women increases the risk of cardiovascular events over 5–10 years is genuinely unknown. The observational data are not clearly concerning, but the prospective long-term randomized data do not exist.
Long-term breast cancer risk. Testosterone can be aromatized to estradiol in breast tissue, and estradiol is a known driver of estrogen-receptor-positive breast cancer. Whether this creates a meaningful net risk increase for women using testosterone at physiologic doses has not been resolved. Some observational data suggest testosterone may be protective against breast cancer through direct androgen receptor pathways. Other data suggest that higher androgen levels in postmenopausal women are associated with slightly increased breast cancer risk — though this is confounded by the fact that higher androgens in older women often reflect underlying metabolic differences. The net effect is genuinely uncertain.
Premenopausal women. Most clinical trials have enrolled postmenopausal women. The safety, efficacy, and appropriate dosing for premenopausal women with androgen deficiency — including those using hormonal contraceptives that suppress endogenous testosterone — is much less well-characterized.
Cognitive effects. Animal models suggest testosterone has neuroprotective and cognitive-enhancing properties in the female brain. Human trial data are sparse and mixed. This is an area where the research gap is particularly wide.
The Argument for and Against Off-Label Use
Given the research gaps, what is the case for using testosterone in women off-label right now?
The argument for is straightforward: for postmenopausal women with documented HSDD, the evidence for benefit is substantial, the evidence for harm at physiologic doses is weak, the professional societies that specialize in this field recommend it, and leaving women with a treatable condition untreated because of regulatory inertia is not neutral — it has real costs.
The argument against, in its strongest form, is not that testosterone doesn’t work. It is that medicine does not fully understand what happens over 10 or 15 years of use in a large population of women, particularly regarding cancer endpoints, and that some clinical caution in the face of genuine uncertainty is appropriate.
The professional consensus in 2025 has landed firmly on the side of the first argument, with appropriate caveats: physiologic-range dosing, consistent monitoring, informed consent that acknowledges the residual uncertainties about long-term safety, and ongoing reassessment.
Where the Field Is Headed
The trajectory of the research is one of gradual accumulation. Large observational studies — including the Women’s Health Initiative extensions, the SWAN (Study of Women’s Health Across the Nation) cohort, and international registry data — continue to add information about long-term outcomes in women with varying androgen levels.
Several Phase II and Phase III trials of novel testosterone formulations for women are in various stages of development globally. Australia has been ahead of the United States in clinical adoption, and the Australian therapeutic guidelines now include specific dosing and monitoring recommendations for female testosterone therapy. The UK’s NICE guidelines have moved in a similar direction.
The FDA approval gap is real and persistent, but the clinical practice — driven by evidence, professional society guidance, and patient demand — is moving forward around it. Whether the regulatory infrastructure catches up remains to be seen.
What is clear is that testosterone is not, and has never been, only a men’s hormone. It was always women’s medicine too. The 80-year delay in recognizing that fully is a story about institutional inertia, naming conventions, pharmaceutical economics, and the particular way that women’s health complaints have historically been filed under “expected” rather than “treatable.” That filing system is being revised, slowly and unevenly, but meaningfully.
This concludes Series 7. Next in The T Files: Series 8 — “The Pill for Men That Never Was” — because the same testosterone science that treats deficiency has also been tantalizing scientists with the possibility of male birth control for the better part of six decades. Why it has not materialized is one of the stranger stories in modern pharmacology.
